To the full analysis
PharmaSGP Holding stock: growth
PSG.DEPharmaSGP Holding reported $131.68M in revenue for fiscal 2024, up 17.5% on the prior year, up 13.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
12.2%
per year from 2017 to 2024, per share 12.4%
Earnings (Annual rate)
7.5%
per year from 2017 to 2024, per share 7.7%
Free cash flow (Annual rate)
7.8%
per year from 2017 to 2024, per share 8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2019 | since 2017 | |
|---|---|---|
| Revenue | 13.7% | 12.2% |
| Revenue per share | 13.9% | 12.4% |
| Earnings | 3.2% | 7.5% |
| Earnings per share | 3.5% | 7.7% |
| Free cash flow | 6.4% | 7.8% |
| Free cash flow per share | 6.6% | 8.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $58.8M | $13.06M | $15.34M |
| 2018 | $67.15M | $16.33M | $9.03M |
| 2019 | $69.34M | $18.51M | $19.06M |
| 2020 | $70.08M | $11.79M | $16.13M |
| 2021 | $72.41M | $11.85M | −$78.92M |
| 2022 | $95.1M | $13.25M | $26.51M |
| 2023 | $112.03M | $18.17M | $28.56M |
| 2024 | $131.68M | $21.65M | $25.93M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Aug 2025
- Latest annual report
- Fiscal year 2024, period end 31 Dec 2024
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 30 Apr 2024)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.